Trial Profile
The current epidemiology of invasive pneumococcal disease (IPD) in children after introduction of 13-valent pneumococcal conjugate vaccine (PCV13)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jan 2020
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections; Streptococcal infections
- Focus Therapeutic Use
- 20 Jan 2020 Results of preliminary framework predicting the patterns of vaccine failure pneumococcal disease cases which may be used in decision making process on the number of doses required for selected populations were published in the Vaccine
- 19 Nov 2018 New trial record
- 07 Oct 2018 Results (n=351) presented at the IDWeek 2018